Denmark based CMC Biologics and US based Inspiration Biopharmaceuticals have signed a supply agreement to manufacturing bulk IB1001 as a treatment and preventive measure of bleeding in individuals with hemophilia B.
The agreement allows CMC Biologics to manufacture bulk IB1001, Inspiration’s intravenous recombinant factor IX product, for at least six years. Further details of the agreement were not disclosed.
Inspiration executive vice president and chief operating officer Andrew Grethlein said they look forward to their continued relationship with CMC Biologics as IB1001 moves toward commercial launch.
